Immunotherapy Added to SABR Improves Event-Free Survival in Early NSCLC

(MedPage Today) -- Stereotactic ablative radiotherapy (SABR) combined with immunotherapy (I-SABR) significantly improved event-free survival (EFS) in patients with early-stage or lung parenchymal recurrent node-negative non-small cell lung cancer...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news